Recognizing that developmental research funds are an integral part of the SPORE, we commit $75,000 per year to these endeavors. In addition, matching funds of $50,000/year are committed to this program from the University of Michigan Medical School. This represents a significant percent of the budget of the UMCC Head and Neck SPORE and reflects the continued commitment of this program to the development of innovative translational research in head and neck cancer. The focus of the Developmental Research Program is to provide investigators the ability to generate data that will become the preliminary data for an R01 grant application of an equivalent proposal. Investigators from outside the field of head and neck cancer are encouraged to apply through campus-wide announcements as well as through personal interactions with SPORE investigators. A stepwise proposal solicitation and review process has been developed utilizing NIH-type PHS 398 format applications that have been streamlined for rapid turn around of research proposals and which recognizes that these projects may have little preliminary data. Investigators may apply for support in the amount of $50,000 for a one- or two-year funding period. Since 2002 we have funded 18 developmental projects, representing a total investment of $790,000;This has resulted in over $2.6 million (direct costs) in subsequent grants, 13 manuscripts, and 4 abstracts. Dr. Gregory Wolf and Dr. Thomas Carey serve as Directors for the Developmental Research Program. Both are leaders in head and neck cancer, and hold institutional leadership positions. Together with the Senior Advisory Council, they are adept at selecting the highest quality proposals for funding and providing the necessary mentorship and support to guarantee success with this program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097248-10
Application #
8382521
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$90,475
Indirect Cost
$87,644
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Matsumoto, Camila S; Almeida, Luciana O; Guimarães, Douglas M et al. (2016) PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget 7:42393-42407
Pearson, Alexander T; Finkel, Kelsey A; Warner, Kristy A et al. (2016) Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget 7:7993-8005
Arthur, Anna E; Bellile, Emily L; Rozek, Laura S et al. (2016) Pretreatment serum xanthophyll concentrations as predictors of head and neck cancer recurrence and survival. Head Neck 38 Suppl 1:E1591-7
Walline, Heather M; Komarck, Christine M; McHugh, Jonathan B et al. (2016) Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. Mol Cancer Res 14:941-952
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2016) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res :
Choi, Seung Hee; Terrell, Jeffrey E; Bradford, Carol R et al. (2016) Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients? Nicotine Tob Res :
Zhang, Yanxiao; Koneva, Lada A; Virani, Shama et al. (2016) Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures. Clin Cancer Res 22:4735-45
Rudy, Shannon F; Brenner, J Chad; Harris, Jennifer L et al. (2016) In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model. J Otolaryngol Head Neck Surg 45:26
Swiecicki, Paul L; Bellile, Emily; Sacco, Assuntina G et al. (2016) A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs 34:481-9
Prince, Victoria; Bellile, Emily L; Sun, Yilun et al. (2016) Individualized risk prediction of outcomes for oral cavity cancer patients. Oral Oncol 63:66-73

Showing the most recent 10 out of 233 publications